Effect of different doses of methotrexate (NSC-740), cytosine arabinoside (NSC-63878), and cyclophosphamide (NSC-26271) on drug resistance in mice with L1210 leukemia.
作者信息
Schmid F A, Hutchison D J
出版信息
Cancer Chemother Rep. 1972 Aug;56(4):473-81.
PMID:5081590
Abstract
摘要
相似文献
1
2
4
Chronochemotherapy of L1210 leukemic mice with cytosine arabinoside or cyclophosphamide.用阿糖胞苷或环磷酰胺对L1210白血病小鼠进行时辰化疗。
Cancer Treat Rep. 1978 Sep;62(9):1337-49.
5
6
Influence of the stage of advancement of leukemia L1210 in mice on the optimal schedule of treatment of cytosine arabinoside (NSC-63878).
Cancer Chemother Rep. 1972 Jun;56(3):327-34.
7
Combination chemotherapy in sequence for the treatment of L1210 leukemia.序贯联合化疗治疗L1210白血病
Cancer Res. 1978 Aug;38(8):2317-20.
8
Dose-related synergism of cytosine arabinoside and methotrexate against murine leukemia L1210.阿糖胞苷与甲氨蝶呤对小鼠白血病L1210的剂量相关协同作用。
Eur J Cancer (1965). 1974 Jul;10(7):425-9. doi: 10.1016/0014-2964(74)90025-5.
9
Combination chemotherapy with cytosine arabinoside, L-asparaginase, and 6-azauridine for transplantable murine leukemias.
Cancer Res. 1973 Apr;33(4):791-9.
10
Studies of the L1210 antileukemic activity of O-2,2'-cyclocytidine, monoacetate (anhydro-ara-C; NSC-129220)--comparison with cytosine arabinoside (NSC-63878) with respect to treatment schedule dependency.O-2,2'-环胞苷单乙酸酯（脱水阿糖胞苷；NSC-129220）的L1210抗白血病活性研究——关于治疗方案依赖性与阿糖胞苷（NSC-63878）的比较
Cancer Chemother Rep. 1972 Aug;56(4):483-92.
Zotero 插件